Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05393895 · ClinicalTrials.gov registry record · Phase 3

An Evaluation of the Safety of CSF-1 in Presbyopic Subjects

A Phase 3 study, sponsored by Orasis Pharmaceuticals.

Completed
Registry status
Phase 3
Development phase
178
Enrollment target

NCT05393895: Completed Phase 3 study, sponsored by Orasis Pharmaceuticals.

NCT05393895 is a Phase 3 study that has completed, run by Orasis Pharmaceuticals. The registered enrollment target is 178 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05393895, a Phase 3 study, has completed, sponsored by Orasis Pharmaceuticals.

COMPLETED
Registry status
Phase 3
Development phase
178 participants
Enrollment target

Study Summary

This is a multi-center, double-masked, vehicle-controlled study. The purpose of the study is to evaluate the safety of CSF-1 compared with vehicle in presbyopic subjects. Subjects will be treated for at least 6 weeks.

Primary Outcome

As this is a safety study, no efficacy outcome has been defined.

Interventions

  • DRUG Vehicle
  • DRUG CSF-1

Trial Details

FieldValue
Enrollment Target 178 participants
Start Date 2022-04-22
Est. Completion 2022-12-01
Phase Phase 3
Orasis Pharmaceuticals

4 total trials

What the finished NCT05393895 record still lists

NCT05393895 is an interventional study that assigns participants to a tested intervention. The registered 178 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (77% lower).

The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.

NCT05393895 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05393895 about?

NCT05393895 is a clinical study titled "An Evaluation of the Safety of CSF-1 in Presbyopic Subjects". This is a multi-center, double-masked, vehicle-controlled study. The purpose of the study is to evaluate the safety of CSF-1 compared with vehicle in presbyopic subjects. Subjects will be treated for at least 6 weeks.

What is the current status of trial NCT05393895?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 178 participants. The study started on 2022-04-22. Estimated completion is 2022-12-01.

What interventions are being tested in trial NCT05393895?

The interventions under investigation include: Vehicle (DRUG), CSF-1 (DRUG).

Who is sponsoring clinical trial NCT05393895?

This trial is sponsored by Orasis Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05393895's enrollment target sits among peer trials

178 1437th of 2000 higher than 563 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03642002 · 178 participants · NA

    The Effects of Music Therapy on Adult Patients Requiring Mechanical Ventilation in the ICU

  • NCT04227847 · 178 participants · Phase 1

    A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

  • NCT04855214 · 178 participants

    Evaluating the Experience of Upper Limb Prosthesis Use

  • NCT05391126 · 178 participants · NA

    GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05393895, the US trial registry maintained by the National Library of Medicine. NCT05393895 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.